NIP
MXCT icon

Nicholas Investment Partners’s MaxCyte MXCT Stock Holding History

Nicholas Investment Partners’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-776,963
Closed -$5.43M – 194
2022
Q1 		$5.43M Sell
776,963
-209,338
-21% -$1.43M 0.39% 94
2021
Q4 		$10.1M Buy
986,301
+6,179
+0.6% +$66.4K 0.64% 56
2021
Q3 		$12M Buy
+980,122
New +$14.8M 0.87% 41

Other funds holding MXCT

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Nicholas Investment Partners's MXCT Position: Q2 2022 in Review

Nicholas Investment Partners sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 776,963 shares — an estimated $5.43M sold.

Nicholas Investment Partners first reported a position in MXCT in Q3 2021 and held it in 3 quarters. The position peaked at $12M in Q3 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

  • Nicholas Investment Partners reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 776,963 MaxCyte shares in Q2 2022, an estimated $5.43M.
  • Nicholas Investment Partners first reported a position in MaxCyte in Q3 2021 and held it in 3 quarters.
  • Nicholas Investment Partners's MaxCyte position peaked at $12M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Nicholas Investment Partners's 13F filing for Q2 2022, filed 10 Aug 2022.